Are 4DMedical and Life360 shares a buy, hold or sell after rocketing 10% yesterday?

This week has been a rollercoaster for ASX investors. 

Monday saw the biggest sell-off in almost a year, as investor sentiment was extremely defensive due to developing conflict in the Middle East. 

It felt as though this was the beginning of an extended decline, as many investors positioned themselves for a risk-off period. 

However before the market crash could even begin, it bounced back yesterday. 

The Motley Fool’s Bernd Struben explained in detail yesterday the factors that are influencing this volatility.

While investors were able to breathe a momentary sigh of relief, there are likely more ups and downs to come. 

What happened to these shares yesterday?

The S&P/ASX 200 Index (ASX: XJO) finished Tuesday a full 1% higher than Monday. 

Two ASX shares that vastly outperformed the benchmark index were 4DMedical Ltd (ASX: 4DX) and Life360 Inc (ASX: 360). 

These stocks rose 9.11% and 10.34% respectively.

This came after crashes of 5% and 7% on Monday. 

What’s more interesting, is these companies are part of two of Australia’s worst performing ASX sectors this year: healthcare and technology.

Following this week’s turbulence, 4DMedical shares are down 2.4% year to date, and up more than 1,000% in the last 12 months. 

Meanwhile, Life360 shares are down 30% year to date and down 2% over the last 12 months. 

With so much movement, it can be difficult for prospective investors to identify an attractive entry point. 

Here is the latest guidance from analysts. 

Life360 shares

For those unfamiliar, Life360’s core product is a private family and friends social networking app that allows users to communicate and share their locations.

It was a strong performer across 2024-2025, however has been heavily sold off this year, most recently on the back of disappointing results.

It closed yesterday at $22.51. 

Based on guidance from brokers, it now looks like an attractive buy. 

Investors will be hoping it has finally hit rock bottom after a tough start to 2026. 

Bell Potter has a recent target of $40.00. 

Recently, Morgan Stanley put an overweight rating and $50.00 price target on Life360 shares. 

These targets indicate an upside in the range of 77% to 122%. 

Based on this guidance, it seems yesterday’s spike could be the beginning of a recovery for Life360 shares. 

Can 4DMedical keep rising?

4DMedical has been one of the hottest ASX shares over the last year. 

It closed yesterday at $4.43 per share, an astounding 1,035.90% higher than 12 months ago. 

It is a medical technology company working in the field of respiratory imaging and ventilation analysis in the treatment of lung and respiratory diseases.

Despite yesterday’s 9% rise, it seems analysts largely see the current share price as hovering close to fair value. 

Analysts forecasts via TradingView have an average one year price target of $4.20 on this ASX stock. 

That’s approximately 5% lower than yesterday’s price target. 

The post Are 4DMedical and Life360 shares a buy, hold or sell after rocketing 10% yesterday? appeared first on The Motley Fool Australia.

More reading

• 4 ASX tech shares tipped to jump up to 140% higher
• Here are the top 10 ASX 200 shares today
• 3 ASX shares to buy for magnificent long-term growth
• 3 ASX tech stocks that brokers rate as buys
• Why are Life360 shares soaring 10% higher today?

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Life360. The Motley Fool Australia has positions in and has recommended Life360. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.